2. Signaling Pathways
  3. Neuronal Signaling
  4. Tau Protein

Tau Protein

Tau is well established as a microtubule-associated protein in neurons. They have roles primarily in maintaining the stability of microtubules in axons and are abundant in the neurons of the central nervous system (CNS). However, under pathological conditions, aberrant assembly of tau into insoluble aggregates is accompanied by synaptic dysfunction and neural cell death in a range of neurodegenerative disorders, collectively referred to as tauopathies.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-173291
    Tau ligand-1
    		Ligand
    Tau ligand-1 (Compound 75) is a ligand for aggregated tau protein that can penetrate the blood-brain barrier. In tissues from patients with Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, and Pick's disease, Tau ligand-1 exhibits high affinity for aggregated tau protein, with equilibrium dissociation constant (KD) values ranging from 1 to 3.8 nM. Tau ligand-1 can serve as a potential positron emission tomography (PET) tracer and holds promise for application in positron emission tomography imaging studies of tau-related diseases in the central nervous system.
    Tau ligand-1
  • HY-P4933
    Tau Peptide (255-314) (Repeat 2 Domain) (human)
    Tau Peptide (255-314) (Repeat 2 Domain) (human) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.
    Tau Peptide (255-314) (Repeat 2 Domain) (human)
  • HY-P991376
    BIIB076
    		Inhibitor
    BIIB076 is a human monoclonal antibody (mAb) targeting PHF-tau. BIIB076 can be used for passive immunity research in Alzheimer's disease (AD).
    BIIB076
  • HY-153431
    TRV-1387
    		Inhibitor
    TRV-1387 is a benzofurazan that inhibits the aggregation of tau and amyloid-β.
    TRV-1387
  • HY-169196
    D-687
    		Inhibitor
    D-687 is an inhibitor of Tau and Aβ. D-687 can reverse Aβ1–42-induced toxicity in SH-SH5Y cells and has significant neuroprotective properties.
    D-687
  • HY-149237
    hAChE-IN-2
    		Inhibitor
    hAChE-IN-2 is a potent hAChE inhibitor, with an IC50 of 0.71 μM. hAChE-IN-2 can also inhibits tau-oligomerization, with an EC50 of 2.21 μM. hAChE-IN-2 exhibits neuroprotective activity.
    hAChE-IN-2
  • HY-172176
    RA-PR058
    		Inhibitor
    RA-PR058 is an orally active Ramalin derivative with blood-brain barrier permeability, exhibiting multi-target regulatory effects and favorable pharmacokinetic properties. RA-PR058 demonstrates potential as a multi-target modulator for Alzheimer's disease by reducing the expression of BACE1, tau protein hyperphosphorylation, and anxiety-like behaviors.
    RA-PR058
  • HY-162812
    H3R antagonist 4
    		Inhibitor
    H3R antagonist 4 (compound 11L) was a dual inhibitor of cholinesterase and histamine receptor (H3R), with corresponding IC50 of 7.04 μM (eeAChE), 9.73 μM (hAChE)(reversible) and 1.09 nM (H3R) , respectively. H3R antagonist 4 inhibited the aggregation of Aβ1-42 induced by itself and Cu2+ (95.48% and 88.63%) , and degraded the Aβ1-42 fibrils induced by itself and Cu2+ (80.16% and 89.30%) . H3R antagonist 4 chelate biometals such as Cu2+, Zn2+, Al3+, and Fe2+. H3R antagonist 4 significantly reduced tau protein hyperphosphorylation induced by Aβ1-42 and inhibited RSL-3-induced apoptosis and ferroptosis in PC12 cells. H3R antagonist 4 had the best blood-brain barrier permeability and intestinal absorption in hCMEC/D3 and hPepT1-MDCK cells.H3R antagonist 4 ameliorates learning and memory impairment in a mouse model of Alzheimer's disease induced by scopolamine (HY-N0296) .
    H3R antagonist 4
  • HY-169197
    D-688
    		Inhibitor
    D-688 is an inhibitor of Tau and Aβ. D-688 can reverse Aβ1–42-induced toxicity in SH-SH5Y cells and has significant neuroprotective properties. D-688 can improve the survival rate of Drosophila melanogaster expressing the human tau protein isoform (2N4R).
    D-688
  • HY-172973
    TAU-IN-4
    		Inhibitor
    TAU-IN-4 (compound I1.21) is a potent Tau aggregation inhibitor with a KD of 1.58 μM. TAU-IN-4 can be used in the study of Alzheimer’s disease.
    TAU-IN-4
  • HY-168079
    GSK-3β inhibitor 21
    		Inhibitor
    GSK-3β inhibitor 21 (compound 44) is an ATP-competitive GSK-3β inhibitor (IC50=6.06 μM) with anti-amyloid aggregation and tau phosphorylation inhibitory activities. GSK-3β inhibitor 21 can be used in the study of Alzheimer's disease.
    GSK-3β inhibitor 21
  • HY-W098905
    GSK3β-IN-3
    		Inhibitor
    GSK3β-IN-3 is an ATP-competitive GSK-3β inhibitor (IC50 = 0.90 μM). GSK3β-IN-3 can reduce the phosphorylation level of tau protein in the BR5706 strain and reduce the deposition of Aβ aggregates in the CL2006 strain, and can be used to research Alzheimer's disease (AD).
    GSK3β-IN-3
  • HY-161458
    GSK-3β inhibitor 16
    		Activator
    GSK-3β inhibitor 16 (compound 7c) is a GSK-3β inhibitor with the IC50 of 4.68 nM. GSK-3β inhibitor 16 decreases Tau hyperphosphorylated aggregate and alleviates cognitive impairments in the Scopolamin (HY-N0296)-induced model in mice.
    GSK-3β inhibitor 16
  • HY-172974
    PTC-700
    		Modulator
    PTC-700 is a potent microtubule-associated protein tau (MAPT) splicing modulator. PTC-700 reduces 4R MAPT in both P301L and S305N neurons with EC50s of 1.3-1.8 nM, and 0.5-2.6 nM, respectively.
    PTC-700
  • HY-P4966
    Tau Peptide (306-336) (Repeat 3 Domain)
    Tau Peptide (306-336) (Repeat 3 Domain) is aTau fragment.
    Tau Peptide (306-336) (Repeat 3 Domain)
  • HY-162750
    ZJCK-6-46
    		Inhibitor
    ZJCK-6-46 (32) is a potential and orally activeDYRK1A inhibitor (IC50 = 0.68 nM) with high BBB permeability (CNS+). ZJCK-6-46 (32) reduces tau phosphorylation. ZJCK-6-46 (32) ameliorates cognitive dysfunction by obviously reducing the expression of phosphorylated tau and neuronal loss in vivo.
    ZJCK-6-46
  • HY-159898
    AChE/BChE-IN-23
    		Inhibitor
    AChE/BChE-IN-23 (Compound 6e) is an AChE/BChE inhibitor (IC50: 0.91 μM, 1.19 μM and 1.01 μM for hAChE, eq BChE and hBChE, respectively). AChE/BChE-IN-23 has antioxidant activity and inhibits Aβ1-42 and Tau protein aggregation. AChE/BChE-IN-23 also inhibits microglial activation by reducing ROS release and mitochondrial injury. AChE/BChE-IN-23 suppresses NLRP3 inflammasome and pro-inflammatory cytokines in human microglial cells. AChE/BChE-IN-23 also reverses the Scopolamine (HY-N0296)-induced memory impairment in mice model.
    AChE/BChE-IN-23
  • HY-P991373
    APNmAb005
    		Inhibitor
    APNmAb005 is a human monoclonal antibody (mAb) targeting MAPT/Tau/PHF-tau. APNmAb005 blocks tau seeding in vitro and rescues neuronal loss in rTG4510 mice. APNmAb005 can be used in Alzheimer’s disease (AD) research.
    APNmAb005
  • HY-176130
    MRL828
    		Degrader
    MRL828 combines a Tau pathology-binding ligand and modified guanine moiety based on the ATTEC technology to selectively designate aggregated tau proteins for clearance via the ALP. MRL828 decreases intracellular Tau aggregates and promotes the secretion of Tau.
    MRL828
  • HY-174215
    TAU-IN-3
    		Inhibitor
    TAU-IN-3 (Compound 2) is an orally active TAU inhibitor. TAU-IN-3 inhibits the expression of MAPT exon 10 DDPAC mutant gene in HeLa cells (IC50: 0.6 µM). TAU-IN-3 reduces the 4R/3R MAPT mRNA ratio in HeLa cells transfected with WT or DDPAC minigenes. TAU-IN-3 inhibits the insertion of endogenous MAPT exon 10 and the production of 4R tau protein in cells. TAU-IN-3 modulates tau splicing in htau mice and improves the associated behavioral phenotypes. TAU-IN-3 can be used to study neurodegenerative diseases.
    TAU-IN-3
Cat. No. Product Name / Synonyms Application Reactivity